NOI to Sole Source AMICUS Apheresis Reagents & Consumables
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The Defense Health Agency Contracting Activity intends to award a firm-fixed-price sole source contract to Fenwal, Inc. for the drop shipment of FDA Fenwal Amicus Apheresis Reagents. This procurement is designed to support the operational requirements of the Naval Hospital Okinawa in Japan, specifically for the collection, treatment, and sustainment of blood platelet products. These reagents and processing sets are critical for pathogen reduction processes mandated by the FDA to ensure patient safety and mission readiness. The contract covers a delivery period from October 1, 2026, through September 30, 2027, with delivery routed through the DLA Troop Support XDock West Project in Ontario, California. Classified under NAICS code 325413, the acquisition is being executed as a sole source because Fenwal, Inc. is identified as the only manufacturer capable of meeting the government's requirements. Interested parties wishing to challenge this intent must submit a detailed capability statement by August 28, 2026.
General Info
Agency
NAICS
Place of Performance
CA, USASet-Aside
Documents
(1)AI Contract Breakdown
Uniform Contract FormatWhat is UCF?
Uniform Contract Format (UCF) uses AI to break down any contract into standardized sections—scope, pricing, deliverables, and evaluation criteria.
Timeline
Response Deadline
Organization & Contact Information
Full Description
Notice of Intent to Sole Source HT941026N0107
THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE SUPPLY CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE QUOTES.
The Defense Health Agency Contracting Activity (DHACA), Healthcare Contracting Division – West (HCD-W), intends to award a firm-fixed-price purchase order for Drop Shipment of FDA Fenwal Amicus Apheresis Reagents (Manufacturer: Fenwal, Inc.). This procurement supports the operational requirements of Naval Hospital Okinawa, Japan, and is conducted in accordance with Federal Acquisition Regulation (FAR) 12.102(a), this acquisition of commercial products and services is being executed as a sole source, as the Contracting Officer does not have a reasonable expectation that two or more offers will be received.
FENWAL, INC., 3 CORPORATE DR STE 300, LAKE ZURICH, IL 60047-8930, United States
UEI: E9UHXHZCGJV5
CAGE: 4Q7Q2
The North American Industry Classification System (NAICS) code for this requirement is 325413, In-Vitro Diagnostic Substance Manufacturing, which has a business size standard of 1,250 employees. The product service code (PSC) is 6550, In-Vitro Diagnostic Substances, Reagents, Test Kits and Sets.
The objective of this sole source award is to procure Amicus Apheresis reagents for the cell separator for Naval Hospital Okinawa, located at Bldg 960, Tarawa Road, Camp Foster, Okinawa, Japan.
The requested Intecept platelet small volume processing set and platelet dual storage containers are used in the Intercept pathogen reducing equipment. These items are vital in the collection, treatment and sustainment of adequate inventory of blood platelets products for routine and emergent patient care and mission requirement. Pathogen reduction of donated blood platelet products reduces the transmission of viruses and infections upon transfusion. US Naval Hospital Okinawa PACOM Armed Services Blood Bank Center (ASBBC) is mandated by FDA to conduct pathogen reduction process for all collected blood platelets. Supplies of the platelet sets are historically sustained thru a drop shipment contract. The suggested vendor is the sole manufacturer and provider of the platelet sets.
Fenwal, Inc., is the only source capable of meeting the government’s minimum requirements.
Delivery Period: 1 October 2026 through 30 September 2027
Delivery Location: MAB, DLA TROOP SUPPORT XDOCK WEST PROJECT, C/O CARDINAL HEALTH MPS DISTRIBUTION CENTER, 4551 EAST PHILADELPHIA STREET, ONTARIO CA 91761
This notice of intent is not a request for competitive proposals, and no formal solicitation document exists for this requirement. Sources interested in responding to this notice are required to submit a capability statement. Submissions must include management, technical, and cost data in sufficient detail accompanied by convincing evidence to clearly demonstrate the capability to provide the required equipment and preventive maintenance. Capability statements shall not exceed four (4) pages (8.5" x 11" format) using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. Requests for documentation, inquiries for additional information, or submissions consisting solely of questions will not be considered affirmative responses. A determination by the Government not to compete this requirement based on responses to this notice is solely within the discretion of the Government. Information received will be considered exclusively for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole-source purchase order.
Response Instructions: If a vendor challenges the basis of this requirement, please email capability statements as a Microsoft Word or Adobe PDF attachment to:
- Mariangela Monsalve at mariangela.j.monsalve.civ@health.mil
- Bobbie Dobberstein at bobbie.s.dobberstein.ctr@health.mil
The closing date for challenges is no later than 1000 Pacific Daylight Time, Friday, August 28, 2026.
NO TELEPHONE REQUESTS/OFFERS WILL BE HONORED.
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Defense → Defense Health Agency Hcd West
Same awarding agency
